Cargando…

Crizotinib for recurring non‐small‐cell lung cancer with EML4‐ALK fusion genes previously treated with alectinib: A phase II trial

BACKGROUND: The efficacy of crizotinib treatment for recurring EML4‐ALK‐positive non‐small cell lung cancer (NSCLC) previously treated with alectinib is unclear. Based on our preclinical findings regarding hepatocyte growth factor/mesenchymal epithelial transition (MET) pathway activation as a poten...

Descripción completa

Detalles Bibliográficos
Autores principales:	Harada, Daijiro, Isozaki, Hideko, Kozuki, Toshiyuki, Yokoyama, Toshihide, Yoshioka, Hiroshige, Bessho, Akihiro, Hosokawa, Shinobu, Takata, Ichiro, Takigawa, Nagio, Hotta, Katsuyuki, Kiura, Katsuyuki
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley & Sons Australia, Ltd 2021
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7919114/ https://www.ncbi.nlm.nih.gov/pubmed/33470536 http://dx.doi.org/10.1111/1759-7714.13825

Ejemplares similares

Mechanisms of Acquired Resistance to ALK Inhibitors and the Rationale for Treating ALK-positive Lung Cancer
por: Isozaki, Hideko, et al.
Publicado: (2015)

A phase I/II trial of weekly nab‐paclitaxel for pretreated non‐small‐cell lung cancer patients without epidermal growth factor receptor mutations and anaplastic lymphoma kinase rearrangement
por: Harada, Daijiro, et al.
Publicado: (2019)

The Role of STAT3 in Non-Small Cell Lung Cancer
por: Harada, Daijiro, et al.
Publicado: (2014)

Cisplatin-induced hyponatremia in malignancy: comparison between brand-name and generic formulation
por: Ochi, Nobuaki, et al.
Publicado: (2014)

Rapid on-site evaluation with BIOEVALUATOR(®) during endobronchial ultrasound-guided transbronchial needle aspiration for diagnosing pulmonary and mediastinal diseases
por: Minami, Daisuke, et al.
Publicado: (2014)

Pharmacologic study (JP28927) of alectinib in Japanese patients with ALK+ non‐small‐cell lung cancer with or without prior crizotinib therapy
por: Hida, Toyoaki, et al.
Publicado: (2016)

Downregulation of TBXAS1 in an iron-induced malignant mesothelioma model
por: Minami, Daisuke, et al.
Publicado: (2015)

Alectinib treatment response in lung adenocarcinoma patient with novel EML4‐ALK variant
por: Song, Peng, et al.
Publicado: (2018)

Efficacy of gilteritinib in comparison with alectinib for the treatment of ALK‐rearranged non‐small cell lung cancer
por: Ando, Chihiro, et al.
Publicado: (2023)

Final overall survival analysis from the phase III J-ALEX study of alectinib versus crizotinib in ALK inhibitor-naïve Japanese patients with ALK-positive non-small-cell lung cancer
por: Hotta, K., et al.
Publicado: (2022)

Role of Survival Post-Progression in Phase III Trials of Systemic Chemotherapy in Advanced Non-Small-Cell Lung Cancer: A Systematic Review
por: Hotta, Katsuyuki, et al.
Publicado: (2011)

Twenty-Seven Years of Phase III Trials for Patients with Extensive Disease Small-Cell Lung Cancer: Disappointing Results
por: Oze, Isao, et al.
Publicado: (2009)

Crizotinib-Resistant Mutants of EML4-ALK Identified Through an Accelerated Mutagenesis Screen
por: Zhang, Sen, et al.
Publicado: (2011)

Activity of second-generation ALK inhibitors against crizotinib-resistant mutants in an NPM-ALK model compared to EML4-ALK
por: Fontana, Diletta, et al.
Publicado: (2015)

Concomitant novel ALK-SSH2, EML4-ALK and ARID2-ALK, EML4-ALK double-fusion variants and confer sensitivity to crizotinib in two lung adenocarcinoma patients, respectively
por: Tao, Hong, et al.
Publicado: (2022)

Durable responses to alectinib in murine models of EML4-ALK lung cancer requires adaptive immunity
por: Kleczko, Emily K., et al.
Publicado: (2023)

Crizotinib: aseptic abscesses in multiple organs during treatment of EML4-ALK-positive NSCLC
por: Weber, Daniel, et al.
Publicado: (2021)

Treatment-Related Death in Patients with Small-Cell Lung Cancer in Phase III Trials over the Last Two Decades
por: Ochi, Nobuaki, et al.
Publicado: (2012)

Cost analysis of the management of brain metastases in patients with advanced ALK+ NSCLC: alectinib versus crizotinib
por: Isla, Dolores, et al.
Publicado: (2020)

Colorectal Cancer with EML4-ALK Fusion Gene Response to Alectinib: A Case Report and Review of the Literature
por: Hsiao, Sheng-Yen, et al.
Publicado: (2021)

Successful Alectinib Treatment for Carcinoma of Unknown Primary with EML4-ALK Fusion Gene: A Case Report
por: Sugiyama, Keiji, et al.
Publicado: (2021)

EML4-ALK rearrangement in primary malignant fibrous histiocytoma of the lung treated with alectinib: A case report
por: Zhang, Shuai, et al.
Publicado: (2022)

A rare double ALK fusion variant EML4-ALK and CDK15-ALK in lung adenocarcinoma and response to crizotinib: A case report
por: Guo, Jun, et al.
Publicado: (2020)

Exposure–response analysis of alectinib in crizotinib-resistant ALK-positive non-small cell lung cancer
por: Morcos, Peter N., et al.
Publicado: (2018)

Three-Year Follow-Up of an Alectinib Phase I/II Study in ALK-Positive Non–Small-Cell Lung Cancer: AF-001JP
por: Tamura, Tomohide, et al.
Publicado: (2017)

lincROR influences the stemness and crizotinib resistance in EML–ALK(+) non-small-cell lung cancer cells
por: Yang, Yonghua, et al.
Publicado: (2018)

Case report: Durable response to alectinib in ALK-rearranged lung adenocarcinoma with acquired, crizotinib-resistant ALK C1156F mutation
por: Rao, Chuangzhou, et al.
Publicado: (2022)

Phase 2 prospective analysis of alectinib in ALK-positive, crizotinib-resistant non-small-cell lung cancer
por: Shaw, Alice T., et al.
Publicado: (2015)

The potential role of HGF-MET signaling and autophagy in the war of Alectinib versus Crizotinib against ALK-positive NSCLC
por: Huang, Xing
Publicado: (2018)

Influence of alectinib and crizotinib on ionizing radiation - in vitro analysis of ALK/ROS1-wildtype lung tissue cells
por: Jost, Tina, et al.
Publicado: (2022)

Receptor ligand-triggered resistance to alectinib and its circumvention by Hsp90 inhibition in EML4-ALK lung cancer cells
por: Tanimoto, Azusa, et al.
Publicado: (2014)

Lung adenocarcinoma harboring complex EML4-ALK fusion and BRAF V600E co-mutation responded to alectinib
por: Guo, Weihong, et al.
Publicado: (2022)

Endobronchial ultrasound-guided transbronchial needle aspiration of hilar and mediastinal lymph nodes detected on (18)F-fluorodeoxyglucose positron emission tomography/computed tomography
por: Minami, Daisuke, et al.
Publicado: (2016)

A Poorly Differentiated Malignant Neoplasm Lacking Lung Markers Harbors an EML4-ALK Rearrangement and Responds to Crizotinib
por: Chung, Jon H., et al.
Publicado: (2014)

Role of chemokine-mediated angiogenesis in resistance towards crizotinib and its reversal by anlotinib in EML4-ALK positive NSCLC
por: Wang, Shasha, et al.
Publicado: (2022)

Magnitude of the Benefit of Progression-Free Survival as a Potential Surrogate Marker in Phase 3 Trials Assessing Targeted Agents in Molecularly Selected Patients with Advanced Non-Small Cell Lung Cancer: Systematic Review
por: Hotta, Katsuyuki, et al.
Publicado: (2015)

Alectinib for choroidal metastasis in a patient with crizotinib-resistant ALK rearranged positive non-small cell lung cancer
por: Okuma, Yusuke, et al.
Publicado: (2015)

Case Report: A Novel Non-Reciprocal ALK Fusion: ALK-GCA and EML4-ALK Were Identified in Lung Adenocarcinoma, Which May Respond to Alectinib Adjuvant-Targeted Therapy
por: Zhai, Xiaoqian, et al.
Publicado: (2022)

Response to crizotinib in a lung adenocarcinoma patient harboring EML4-ALK translocation with adnexal metastasis: A Case Report
por: Wang, Wenxian, et al.
Publicado: (2016)

The Impact of Clinical Factors, ALK Fusion Variants, and BIM Polymorphism on Crizotinib-Treated Advanced EML4–ALK Rearranged Non-small Cell Lung Cancer
por: Lin, Yen-Ting, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_iadvmfd9lmdcthvfdgdaurdn3c